Ubs Group Ag Cure Vac N.V. Put Options Transaction History
Ubs Group Ag
- $528 Billion
- Q1 2025
Put Options
1 transactions
Others Institutions Holding CVAC
# of Institutions
94Shares Held
10.7MCall Options Held
75.1KPut Options Held
86.7K-
Black Rock Inc. New York, NY2.25MShares$10.1 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.82MShares$8.12 Million0.0% of portfolio
-
Bill & Melinda Gates Foundation Seattle, WA1.57MShares$7.01 Million10.6% of portfolio
-
Gsa Capital Partners LLP London, X0308KShares$1.38 Million0.08% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL280KShares$1.25 Million0.0% of portfolio
About CureVac N.V.
- Ticker CVAC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 187,467,008
- Market Cap $838M
- Description
- CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...